Seligmann H, Halkin H, Rauchfleisch S, Kaufmann N, Motro M, Vered Z, Ezra D
Division of Clinical Pharmacology, Sheba Medical Center, Tel Hashomer, Israel.
Am J Med. 1991 Aug;91(2):151-5. doi: 10.1016/0002-9343(91)90007-k.
To test the hypothesis that long-term furosemide therapy in patients with congestive heart failure (CHF) is associated with clinically significant thiamine deficiency via urinary loss.
(1) Biochemical evaluation of thiamine status in hospitalized patients with CHF treated with long-term furosemide and in age-matched control patients. (2) Uncontrolled trial of the effect of intravenous thiamine on cardiac performance in a subset of six patients with CHF.
General medical ward of a teaching community hospital.
Twenty-three patients with chronic CHF receiving furosemide, and 16 age-matched control patients without heart failure and not taking diuretics. Daily furosemide doses were 80 to 240 mg, and duration of furosemide therapy was 3 to 14 months. Patients with identifiable causes of inadequate thiamine intake, absorption, or utilization or increased metabolic requirements were excluded.
A 7-day course of intravenous thiamine, 100 mg twice daily, in six consenting patients with CHF.
A high thiamine pyrophosphate effect (TPPE), indicating thiamine deficiency, was found in 21 of 23 furosemide-treated patients and in two of 16 controls (p less than 0.001). The mean (+/- SE) TPPE (normal: 0% to 15%) in furosemide-treated and control patients was 27.7 +/- 2.5% and 7.1 +/- 1.6%, respectively (p less than 0.001). Despite the high TPPE, the mean (+/- SE) urinary thiamine excretion in the furosemide-treated patients (n = 18) was inappropriately high (defined as greater than 130 micrograms/g creatinine), 410 +/- 95 micrograms/g creatinine, even in comparison with that in the controls (n = 14): 236 +/- 69 micrograms/g creatinine. In six patients treated with intravenous thiamine, the elevated TPPE decreased to normal, from a mean (+/- SE) of 27.0 +/- 3.8% to 4.5 +/- 1.3% (p less than 0.001), indicating normal thiamine utilization capacity. Left ventricular ejection fraction increased in four of five of these patients studied by echocardiography.
These preliminary findings suggest that long-term furosemide therapy may be associated with clinically significant thiamine deficiency due to urinary loss and contribute to impaired cardiac performance in patients with CHF. This deficit may be prevented or corrected by appropriate thiamine supplements.
检验以下假设,即充血性心力衰竭(CHF)患者长期使用呋塞米治疗会因尿液流失导致具有临床意义的硫胺素缺乏。
(1)对接受长期呋塞米治疗的住院CHF患者及年龄匹配的对照患者进行硫胺素状态的生化评估。(2)对6例CHF患者的一个亚组进行静脉注射硫胺素对心脏功能影响的非对照试验。
一所教学社区医院的普通内科病房。
23例接受呋塞米治疗的慢性CHF患者,以及16例年龄匹配、无心力衰竭且未服用利尿剂的对照患者。呋塞米的每日剂量为80至240毫克,呋塞米治疗的持续时间为3至14个月。排除有可识别的硫胺素摄入、吸收或利用不足原因或代谢需求增加的患者。
对6例同意参与的CHF患者进行为期7天的静脉注射硫胺素治疗,每日两次,每次100毫克。
23例接受呋塞米治疗的患者中有21例以及16例对照患者中有2例出现硫胺素焦磷酸效应(TPPE)升高,提示硫胺素缺乏(p<0.001)。接受呋塞米治疗的患者和对照患者的平均(±标准误)TPPE(正常:0%至15%)分别为27.7±2.5%和7.1±1.6%(p<0.001)。尽管TPPE升高,但接受呋塞米治疗的患者(n = 18)的平均(±标准误)尿硫胺素排泄量仍异常高(定义为大于130微克/克肌酐),为410±95微克/克肌酐,即使与对照患者(n = 14)相比也是如此:236±69微克/克肌酐。在6例接受静脉注射硫胺素治疗的患者中,升高的TPPE降至正常,从平均(±标准误)的27.0±3.8%降至4.5±1.3%(p<0.001),表明硫胺素利用能力正常。通过超声心动图研究的这5例患者中有4例左心室射血分数增加。
这些初步发现表明,长期使用呋塞米治疗可能因尿液流失导致具有临床意义的硫胺素缺乏,并导致CHF患者心脏功能受损。这种缺乏可通过适当补充硫胺素预防或纠正。